Allianz Asset Management GmbH Has $49.41 Million Stake in DaVita Inc. $DVA

Key Points

• Allianz Asset Management GmbH reduced its stake in DaVita Inc. by 15.2% during the second quarter, now owning 346,883 shares valued at approximately $49.41 million.
• DaVita reported earnings per share of $2.95 for the last quarter, exceeding analysts' estimates, with a revenue of $3.38 billion.
• Institutional investors hold 90.12% of DaVita's shares, indicating significant institutional interest in the company.

Allianz Asset Management GmbH lessened its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 15.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 346,883 shares of the company's stock after selling 61,944 shares during the period. Allianz Asset Management GmbH owned 0.46% of DaVita worth $49,413,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Farther Finance Advisors LLC grew its stake in shares of DaVita by 199.7% in the 1st quarter. Farther Finance Advisors LLC now owns 1,070 shares of the company's stock worth $163,000 after acquiring an additional 713 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of DaVita in the 1st quarter worth $846,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of DaVita by 22.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock worth $666,000 after acquiring an additional 800 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of DaVita by 8.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after acquiring an additional 79 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in shares of DaVita by 0.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,180 shares of the company's stock worth $3,852,000 after acquiring an additional 160 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

Insider Activity

In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company's stock.

DaVita Trading Up 0.4%

Shares of DaVita stock opened at $125.79 on Friday. DaVita Inc. has a 12-month low of $122.93 and a 12-month high of $179.60. The company has a market cap of $8.99 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 0.90 and a beta of 1.13. The company's 50-day moving average price is $132.49 and its 200-day moving average price is $138.42.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the firm posted $2.00 earnings per share. The company's revenue for the quarter was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a "hold (c+)" rating on shares of DaVita in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of DaVita from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Barclays cut their price target on shares of DaVita from $160.00 to $149.00 and set an "equal weight" rating on the stock in a report on Thursday, October 9th. Truist Financial set a $140.00 price target on shares of DaVita in a report on Tuesday. Finally, Bank of America dropped their price objective on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday, September 10th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $153.25.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.